Literature DB >> 10915173

Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates.

W R Kim1, R H Wiesner, J J Poterucha, T M Therneau, J T Benson, R A Krom, E R Dickson.   

Abstract

The Mayo natural history model has been used widely as a tool to estimate prognosis in patients with primary biliary cirrhosis (PBC), particularly liver transplant candidates. We present an abbreviated model in which a tabular method is used to approximate the risk score, which may be incorporated in the minimal listing criteria for liver transplant candidates. Data used in the development and validation of the original Mayo model were derived from 418 patients with well-characterized PBC. To construct an abbreviated risk score in a format similar to that of Child-Turcotte-Pugh score, 1 to 3 cut-off criteria were determined for each variable, namely age (0 point for <38, 1 for 38 to 62 and 2 for >/=63 years), bilirubin (0 point for <1, 1 for 1 to 1.7, 2 for 1.7 to 6.4, and 3 for >6.4 mg/dL), albumin (0 point for >4.1, 1 for 2.8 to 4.1, and 2 for <2.8 g/dL), prothrombin time (1 point for normal and 2 for prolonged) and edema (0 point for absent and 1 for present). The intervals between these criteria were chosen in a way to enable a meaningful classification of patients according to their risk for death. This score is highly correlated with the original risk score (r = 0.93; P <.01). The Kaplan-Meier estimate at 1 year was 90.6% in patients with a score of 6. The abbreviated risk score is a convenient method to quickly estimate the risk score in patients with PBC. An abbreviated score of 6 may be consistent with the current minimal listing criteria in liver transplant candidates.

Entities:  

Mesh:

Year:  2000        PMID: 10915173     DOI: 10.1053/jlts.2000.6503

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  12 in total

1.  Association between fatigue and decreased survival in primary biliary cirrhosis.

Authors:  Claudia O Zein; Arthur J McCullough
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

2.  38-year-old woman with abnormal liver enzymes and hyperlipidemia.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

3.  Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?

Authors:  Antonio Maria Alfano; Alessandra Romito; Cristiana Marchese; Marco Battistini; Giliola Crotti; Arturo Ferrini; Cristina Mancinetti; Tilde Manetta; Giulio Mengozzi; Paola Merlach; Marco Migliardi; Maria Teresa Tambuzzo
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 4.  A brief review on prognostic models of primary biliary cholangitis.

Authors:  Sha Chen; Weijia Duan; Hong You; Jidong Jia
Journal:  Hepatol Int       Date:  2017-09-14       Impact factor: 6.047

5.  Surgical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Florian Loehe; Rolf J Schauer
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 6.  Value of Liver Function Tests in Cirrhosis.

Authors:  Praveen Sharma
Journal:  J Clin Exp Hepatol       Date:  2021-11-14

7.  Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment.

Authors:  Meri Koulentaki; Joanna Moscandrea; Philipos Dimoulios; Costas Chatzicostas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 8.  Recurrence of cholestatic liver disease after living donor liver transplantation.

Authors:  Sumihito Tamura; Yasuhiko Sugawara; Junichi Kaneko; Junichi Togashi; Yuichi Matsui; Noriyo Yamashiki; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 9.  Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Authors:  Treta Purohit; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2015-05-08

10.  Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis.

Authors:  Stella Gabeta; Gary L Norman; Christos Liaskos; Panagiotis A Papamichalis; Theodoros Zografos; Athanasios Garagounis; Eirini I Rigopoulou; George N Dalekos
Journal:  J Clin Immunol       Date:  2007-05-21       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.